Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.06.022
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV


Related search